Physician profile
Sarah Hull
NPI 1366093312
$5,682.89
in general payments reported to CMS, 2019-2025
14 companies · $1,599 in 2025
The $1,599 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $210 · 2023: $416 · 2024: $3,156 · 2025: $1,599.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,717 · Travel and Lodging: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,717.32 |
| Travel and Lodging | $1,453.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $4,053.54 | 2024-2025 | |
| Royal Biologics, INC. | $426.09 | 2025 | |
| Hartmann USA, INC. | $312.60 | 2021-2024 | Zetuvit Plus, Zetuvit Plus 10x10 P10 |
| Abbvie INC. | $164.72 | 2021-2023 | |
| Paratek Pharmaceuticals, INC. | $136.41 | 2021-2024 | Nuzyra |
| Smith+Nephew, INC. | $122.97 | 2022-2024 | Grafix Pl, Regranex, Collagenase Santyl |
| Organogenesis INC. | $121.71 | 2022-2025 | Apligraf |
| Neurelis, INC. | $85.17 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $69.10 | 2022 | |
| Novo Nordisk INC | $62.27 | 2021 | |
| Convatec INC. | $55.14 | 2024 | |
| Biowound Solutions, INC. | $37.65 | 2025 | Bio-Connekt |
| Hydrofera LLC | $21.30 | 2024 | Hydrofera Blue |
| Advanced Oxygen Therapy INC. | $14.22 | 2024 | Topical Oxygen Chamber For Extremities |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.